1. Naamidine A reveals a promising zinc-binding strategy for topical antifungal therapy.
- Author
-
Puumala E, Nabeela S, Thornburg CC, Grkovic T, Uppuluri P, Whitesell L, O'Keefe BR, Robbins N, and Cowen LE
- Subjects
- Animals, Mice, Trichophyton drug effects, Drug Resistance, Fungal drug effects, Terbinafine pharmacology, Terbinafine therapeutic use, Disease Models, Animal, Humans, Tinea drug therapy, Tinea microbiology, Dermatomycoses drug therapy, Arthrodermataceae, Antifungal Agents pharmacology, Antifungal Agents therapeutic use, Zinc, Administration, Topical, Microbial Sensitivity Tests
- Abstract
Fungal disease affects over a billion people worldwide. Naamidine A inhibits the growth of diverse fungal pathogens through an unknown mechanism. Here, we show that the supplementation of medium with excess zinc abolishes the antifungal activity of naamidine A. Furthermore, we highlight that naamidine A has in vitro activity against terbinafine-resistant Trichophyton spp . and in vivo efficacy in a mouse model of dermatomycosis caused by T. mentagrophytes, highlighting its therapeutic potential as a topical treatment., Competing Interests: L.E.C. and L.W. are co-founders and shareholders in Bright Angel Therapeutics, a platform company for the development of novel antifungal therapeutics. L.E.C. is a Science Advisor for Kapoose Creek, a company that harnesses the therapeutic potential of fungi.
- Published
- 2024
- Full Text
- View/download PDF